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1.1. PET: POSITRON EMISSION TOMOGRAPHY 
1.1.1. Overview 
Positron emission tomography (PET) is one of the most sensitive and specific technique 
for imaging molecular pathways in vivo and in a non-invasive way. It is based on the 
administration of compounds labeled with short-lived positron-emitting radionuclides to 
obtain three-dimensional images of functional processes in animals and/or humans. 
Typical isotopes used as radionuclides in PET are fluorine-18, carbon-11, nitrogen-13 
and oxygen-15 (see Table 1.1 for physical properties). These radionuclides are 















97% β+ 3% EC* 
Oxygen-18 
0.69 0.202  2.4 mm 
Carbon-11 20.4 
100 % β+ 
Boron-11 
0.96 0.326  4.1 mm 
Nitrogen-13 9.98 
100 % β+ 
Carbon-13 
1.19 0.432  5.4 mm 
Oxygen-15 2.05 
100 % β+ 
Nitrogen-15 
1.70 0.650  8.0 mm 
Table 1.1: Physical characteristics of fluorine-18, carbon-11, nitrogen-13 and oxygen-15. *EC: Electronic 
capture. Obtained from: Welch, M.J; Redvanly, C.S; Handbook of radiopharmaceuticals: Radiochemistry 
and applications; Wiley, 2005. 
 
The spontaneous decay of a positron emitter produces a positron, which travels a certain 
distance (depending on its energy) to finally react with one electron of a surrounding 
atom. This process is called annihilation; as a result, two gamma photons are emitted 
(511 keV each, emitted at 180º to each other, Figure 1.1). The generation of these 
gamma rays is the basis of positron emission tomography. When a tracer containing a 
positron emitter is administered to an organism, the high-energy gamma rays produced, 
which have a high penetration power, escape from the body and are detected by an 
 
external ring of detectors as a coincident event
of thousands of such coincident events permits the reconstruction of a 
contains information about
organism. 
The most commonly used PET 
crystals. These crystals are usually made of high density materials to enhance 
interaction with gamma rays and are
intrinsic resolution is determined 
the individual detectors. Hence, resolution can be enhanced by reducing the dimension 
of the detector crystals.  
 
 
Figure 1.1: Positron annihilation process: spontaneous radioactive decay of positron emitters 
(carbon-11 in the example) produces the emission of a positron, whose energy is lost until 
reaction with one electron of a surrounding atom leads to the annihilation process
consequent formation of two 511 keV gamma rays, 180º
11 is converted into boron-11. 
 
Figure 1.2: Positron annihilation pro
180º to each other. These two gamma ray
penetration power and are detected by an external ring of detectors (sited into the PET 
camera) as coincident events.
 (Figure 1.2). The detection of 
 the distribution of the radiolabeled tracer
detection system consists of an array of scintillation 
 optically coupled to several photo
by the number of detectors on the array 
 to each other. In the example, carbon
 
 
duces the formation of two 511 keV gamma rays, 
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Several physical restrictions (as positron range, Compton scattering, angulation, 
accidental coincidences and detector dead-time)2 impose a spatial resolution of 2-3 mm 
in clinical (human dedicated) scanners and 0.5-1 mm in preclinical (small animal 
dedicated) scanners.3 Spatial resolution of PET scanners is lower than that obtained with 
anatomical imaging techniques like magnetic resonance imaging (MRI) or computed 
tomography (CT), but information about biological and/or physiological processes can 
be obtained at a molecular level (see Figure 1.3).4  
Data from PET cameras are obtained as sinograms that are reconstructed into 
tomographic images after correction for attenuation and detector efficiency by using 
different methods. From the reconstructed images, time-activity curves can be derived. 
In many PET studies, the objective is not just to visualize a specific activity but to 
obtain quantitative or semi-quantitative data. Two values are typically calculated: (i) 
%ID/g, percent injected dose per gram of tissue and (ii) SUV, standardized uptake value 










Figure 1.3: Spectrum of medical imaging. The sensitivity range covers from millimolar (top) to 
picomolar (bottom). X-ray, CT and MRI give accurate structural information with high resolution. 
Nuclear imaging techniques (PET and SPECT) have lower resolution but offer pharmacokinetic and 
pharmacodynamic information. CT, computed tomography; MRI, magnetic resonance imaging; US, 
ultrasound imaging; MRS, magnetic resonance spectroscopy; PET, positron emission tomography; 
SPECT, single photon emission computerized tomography. Adapted from: Price, P; PET as a potential 
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Equation 1: Standardized uptake value (SUV). 
PET was first used for oncologic studies in the 1970s, and nowadays it is a clinically 
established technology and suited for translational applications. The high sensitivity of 
the method allows the use of trace concentrations that are below the pharmacological 
effective dose (typical synthesis scales are in the order of 0.2 µmol). This fact has an 
impact on the regulatory approval process of PET radiotracers (extended to the safety 
and toxicology), and facilitates the availability of such radiotracers for clinical studies.5 
Although PET technology can be applied to approach a large variety of physiological, 
biological and/or medical questions, both in the preclinical and in the clinical areas, the 
development of (new) labeled species is required. This development requires a 
multidisciplinary approach regarding: (i) target selection, (ii) organic synthesis, (iii) 
radiolabeling, (iv) in vitro and in vivo evaluation and (v) kinetic modeling of the data. 
The first step in the development of new PET radiotracers is the identification of the 
target which generally consists of an enzyme, a transporter, a receptor or any other 
biomolecule that allows high affinity binding of the compound. Taking into account the 
limited resolution of PET (specially compared to other imaging techniques), the volume 
of the affected tissue should be compatible with the resolution of PET cameras. In some 
cases the high affinity of the radiotracer is a limiting factor and some modifications are 
needed to reduce this affinity; such is the case of displacement studies.  
Once the target has been identified, rational design of the adequate radiotracer based on 
structural biology and high throughput screening of libraries of compounds is used to 
select the best ligand/s. 
Moreover, and before performing studies with the labeled specie, there are some in vitro 
experiments that can be done using the non radioactive compound, such as metabolism, 
binding and affinity. Compounds with the best results during in vitro assays (concerning 
pharmacokinetics and target affinity) are selected for in vivo studies.  
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The first key factor to be considered when planning in vivo studies is the choice of the 
radionuclide, whose physical characteristics will define the applicability of the labeled 
specie. Thus, the energy of the positron has an effect on image resolution, while half-
life of the radionuclide should be long enough to perform the radiolabeling, purification, 
formulation and quality control of the final product. Moreover, half-life of the 
radioisotope should match the biological half-life of the radiotracer, in order to allow a 
complete pharmacokinetic study while dose exposure is minimized. 
Once the radiotracer is ready for use, some in vitro assays (e.g., determination of 
binding and stability in plasma) may be done before performing in vivo studies. 
Typically, first in vivo studies for a newly developed radiotracer consist of a 
biodistribution assay for the determination of its pharmacokinetic properties. If the 
resolution of the technique is not enough, ex vivo autoradiography studies can be 
performed to visualize the distribution of the radiotracer, although in this case 
longitudinal studies within the same subject (animal) are not possible. 
1.1.2. PET isotopes: general aspects 
Among all radionuclides, only a few of them have the adequate physical properties to 
become suitable candidates for the preparation of radiotracers. In the particular case of 
positron emitters, there are four radioisotopes which have been historically used: 
carbon-11, nitrogen-13, fluorine-18 and oxygen-15. The wide historical use of these 
isotopes is due to (i) they can be produced in relatively high yields in commercially 
available cyclotrons, (ii) they can be easily introduced in a biomolecule, (iii) their decay 
mode is close to 100% positron emission (Table 1.1) and (iv) their stable isotopes are 
present in all organic molecules; this last statement is not true in the case of fluorine, but 
in many cases the substitution of an hydroxyl group (or hydrogen atom) by a fluorine 
atom does not dramatically alter the biological behavior of the molecule; thus fluorine 
can be used to prepare analogs of molecules with specific biological roles. 
Many positron-emitters can be generated in a cyclotron, where a specific target is 
irradiated with high energy protons (8-19 MeV) to produce a nuclear reaction with 
subsequent formation of the positron emitter. The number of reactions that take place in 
the target depend on many factors. Thus, the energy of the proton beam and the 
chemical composition of the target (including impurities) define the radioisotopes 
produced during beam. On the other hand, the chemical form of the final product can be 
9 
 
modified by changing either the chemical composition or the physical state of the target 
during irradiation. Other factors like the presence of radical scavengers and/or 
moderators in the target can modulate chemical reactions taking place within the target. 
Among all PET isotopes, fluorine-18 is probably the most widely used, especially for 
clinical applications. Fluorine-18 forms strong covalent bonds with carbon atoms and 
can be incorporated into a large variety of organic molecules; moreover, substitution of 
a hydrogen atom by a fluorine atom causes little steric alterations in the molecule; in 
some particular cases, the biological properties of the radiotracer are even improved 
with respect to the original molecule (such is the case of [18F]FDG, a radiotracer used in 
the clinical environment for diagnostic of some types of cancer). Fluorine-18 has a 
small positron range and its half-life is relatively long (109.8 min) allowing the 
preparation of complex molecules with acceptable radiochemical yields. The relatively 
long half-life permits the commercialization of radiotracers as diagnostic tools in the 
clinical environment.  
Out of the above mentioned clinical environment, other positron emitters like carbon-11 
and nitrogen-13 have a huge potential for the synthesis of radiotracers. The 
manufacturing process of radiotracers with these two positron emitters presents some 
difficulties because of their short half-life (20.4 and 9.98 min, respectively). Carbon-11 
can be obtained in cyclotrons in different chemical forms, depending on the irradiated 
material and the environment during irradiation; however, two chemical forms are, by 
far, the most commonly used radioactive precursors for labeling molecules: [11C]CO2 
(obtained by irradiating N2/O2 mixtures) and [
11C]CH4 (obtained by irradiation of  N2/H2 
mixtures). Nitrogen-13 is obtained by irradiation of water solutions and is usually 
produced as [13N]NH4
+ after irradiation of diluted ethanol aqueous solutions; this 
radiochemical specie has direct application in the clinical environment as perfusion 
marker.  
Oxygen-15 is the shortest-lived positron emitting isotope of oxygen. Its half-life is 2.05 
minutes, and it is historically one of the first artificial radioisotopes produced with low 
energy deuterons on a cyclotron. It does not have many applications due to its short 




1.1.3. PET isotopes: production 
Principles of cyclotron 
A cyclotron (See Figure 1.4 for general schematic) is a particle accelerator in which an 
electric field is used to accelerate ions, such as H- or D-, and a magnetic field is applied 
to “guide” them. The electric field is generated by the application of an electric potential 
difference to two electrodes (called dees and counter-dees), which are connected to the 
alternating current source (radiofrequency generator). Negative ions are generated in the 
ion source (placed in the center of the cyclotron) by applying a high voltage to hydrogen 
(or deuterium) gas. Negative ions are extracted from the center of the cyclotron by 
applying an electrical field. When the dee is positively charged, the counter dee is 
negatively charged. Thus, the ion is accelerated towards the dee by the electric field. 
Once the ion enters the hole of the dee it experiences only the magnetic field. When the 
ion leaves the dee, the polarity on the dees is reversed, so that the ion is accelerated 
again to the counter dee. The same process is repeated in the other dee, but the orbit 
radius is higher as the speed of the ion is higher. This process continues and the ion is 
spiraling outward towards the border of the magnetic field. When the radius reaches a 
certain value, the negative ions hit a stripping foil (usually graphite) which removes the 
electrons. The charged ion, now positive, experiences the same force in the same 
direction but with opposite sense (Figure 1.5), leaves the magnetic field and continues 
to an external target position, where collision with the target material takes place and 
radioactive atoms are generated (see Figure 1.6 for physical target structure).  
Before the collision with the target, the ion gets an energy which is equal to the sum of 
all individual accelerations in the gaps between the dees and the counter dees. The final 
kinetic energy is determined by the nature of the ion and the size of the magnet. 
Negative particle cyclotrons have some advantages with respect to positive particle 
ones: (i) the ability to easily have a variable energy cyclotron, by moving the extraction 
foil to different radii, (ii) almost 100% extraction, due to the extraction through the 
stripping foil, and (iii) being able to extract multiple beams simultaneously, by inserting 
the extraction foils in a way that only intercept part of the beam, allowing the remainder 




Figure 1.4: General view of the main body of an IBA Cyclone 18/9 cyclotron. Some parts (ion sources, 
strippers and targets) have been removed from the drawing. The electrical current passing through the 
coils (3) that surround the four wedge-shaped steel sectors (1) creates the magnetic field. Dees 
(highlighted in red) are placed between the steel sectors and counter dees (not shown in the drawing) are 
placed on the edges of the four steel sectors close to the dees. For dual particle cyclotrons (acceleration of 
H- and D-), small steel sectors called flaps (2) can be introduced or removed to modulate the magnetic 




Figure 1.5: Negative ions are accelerated until they 
hit a stripping foil, which removes the electrons. The 
ion charge, now positive, experiences the same force 
in the same direction but with opposite sense, leaving 
the cyclotron and hitting the selected target. Adapted 
from: IBA users manual. 
Figure 1.6: Liquid target for the production of 
[18F]F- in an IBA Cyclone 18/9 cyclotron. 
Positive ions deflected by the stripper collision 
with the target material to produce the 



















Most important characteristics for a cyclotron dedicated to clinical and preclinical 
research in PET are: 
 Two particles can be accelerated (proton-deuteron). Protons are needed for the 
production of carbon-11, nitrogen-13 and fluorine-18 and deuterons are required 
for the production of oxygen-15. Currently, methods for the production of 
oxygen-15 using protons instead of deuterons are being developed with 
promising results.7 
 Fixed energy. The same energy can be used for the production of carbon-11, 
nitrogen-13 and fluorine-18. A lower deuteron energy for the production of 
oxygen-15 is enough. The energy of the beam can be modulated by the insertion 
of energy degraders (eg., aluminum foils) into the trajectory of the accelerated 
ions. Many applications are found in the irradiation of solid targets for the 
production of non-conventional isotopes, like Ti-45, Zr-89, etc. 
 Simple design and operation. 
Targets 
The target is a container where the target material to be irradiated (usually gas or liquid, 
but solid materials are also used) is introduced. There are some key parameters which 
have to be considered for target body design:  
 The threshold energy for the reaction, to say, the minimal energy needed to 
generate the radioactive atom. 
 The energy where the maximum cross-section (probability for the nuclear 
reaction to occur) is obtained.  
 The physical form of the target material: gas, liquid or solid. Heat transfer 
properties and potential effects due to heating while irradiation takes place 
should be carefully considered for each particular case.  
 The chemical form of the target material. 
 The physical form of the product. 
 The chemical form of the product. 
 The ease of separation of the product from the target. 
Targets specially designed for the production of the most common positron emitters 
(fluorine-18, carbon-11, nitrogen-13 and oxygen-15) are implemented in commercially 
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available cyclotrons and its design to improve its performance has been optimized for 
many years. 
Production of fluorine-18 
There are different nuclear reactions to produce fluorine-18 (see Table 1.2). However, 
the most widely used reactions are 20Ne(d,α)18F and 18O(p,n)18F, because both reactions 
require moderate particle energy and low current beam to give useful yields.  
Despite only the above mentioned nuclear reactions are routinely used, the variety in the 
design of fluorine-18 targets is very large. The first nuclear reaction (20Ne(d,α)18F) is 
used to prepare carrier-added (CA) [18F]fluorine  (as 18F2) and the second one is used to 
produce no-carrier-added (NCA) [18F]fluorine as 18F- (no-carrier-added is the 
preparation of a radioactive isotope which is essentially free from stable isotopes of the 
element. It is also called carrier free). In the last years, the nuclear reaction 18O(p,n)18F 
has been also used for the production of carrier added [18F]fluorine as 18F2.
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Nuclear reaction Useful Energy Range (MeV) Natural Abundance (%) 
18O(p,n)18F 4 - 14 0.2 
16O(3He,p)18F 1 - 15 99.7 
16O(3He,n)18Ne:18F 15 - 40 99.7 
16O(4He,np)18F 20 - 40 99.7 
16O(4He,2n)18Ne:18F 10-52 99.7 
20Ne(d, α)18F 0-15 90.5 
20Ne(p,2pn)18F 30-40 90.5 
20Ne(3He, α p)18F 10-40 90.5 
Table 1.2: Nuclear reactions used for obtaining fluorine-18. Natural abundance refers to the irradiated 
stable isotope for the production of 18F.  Obtained from: Welch, M.J; Redvanly, C.S; Handbook of 




Although nowadays the NCA procedure is the routine process to obtain fluorine-18, 
which is mostly used to produce 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG), a well-
established radiotracer used in clinical applications, mainly, for oncologic diagnostic, 
for some applications carried added [18F]fluorine can be an advantage to label certain 
molecules by electrophilic substitution to do in vivo PET studies, 9 and thus the reaction 
20Ne(d,α)18F is used. Moreover, in some cases, the synthetic route to obtain the 
radiotracer is easier if the chemical specie [18F]F2 is used, and thus [
18F]F2 has also 
some important applications. 
Regarding the production of 18F-, in the last decades several targets made from silver or 
titanium have been used, either applying high or low pressure during irradiation. Silver 
targets have a high thermal conductivity, but they have the disadvantage that colloids 
can be formed during irradiation, which can lead to increase the target pressure, 
decreasing thus the reaction yield. On the other hand, titanium is inert, but effective 
cooling is a disadvantage. In addition, the radioisotope vanadium-48 is produced as a 
byproduct, which contaminates the enriched water and causes high radiation levels in 
the cyclotron bunker by accumulation in the target foils. In the recent years, niobium, an 
inert metal with higher thermal conductivity than titanium, is the most widely used 
material for targets designed for the production of 18F-.  
When the reaction 20Ne(d,α)18F is used, it is necessary to add non radioactive F2 to the 
target because F2 is very reactive and can be absorbed into the target walls and transfer 
lines (from the target to the synthesis modules in the radiochemistry laboratory). This 
essential step is called passivation and it is critical to obtain good yields.  
Production of carbon-11 
Carbon-11, due to its short half-life, is not easy to transport from manufacturing centers 
to surroundings hospitals. Thus, carbon-11 began to receive increasing attention as a 
useful nuclide in medical application in the sixties due to the widespread installation of 
cyclotrons in hospitals. 
The nuclear reactions able to produce carbon-11 are shown in Table 1.3. By far, the 
most common reaction is 14N(p,α)11C using nitrogen gas as irradiated material. This 
reaction produces carbon-11 with high yields and, with the addition of oxygen, all 
carbon-11 is obtained in the chemical form of [11C]CO2. The presence of oxygen in the 
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target mixture generates unwanted [13N]-labeled nitrogen oxides which are not useful 
because they are converted into [13N]N2 in the target.
10 With the addition of hydrogen 
instead of oxygen, [11C]CH4 can be produced. 
Nuclear reaction Useful Energy Range (MeV) % Natural Abundance 
11B(p,n)11C 5-20 80.1 
10B(d,n)11C 3-12 19.9 
12C(p,pn)11C 20-50 98.9 
14N(p,α)11C 7-15 99.6 
14N(d,n α)11C 10-15 99.6 
12C(3He, α)11C 7-15 98.9 
Table 1.3: Nuclear reactions used for obtaining carbon-11. Natural abundance refers to the irradiated 
stable isotope for the production of 11C. Obtained from: Welch, M.J; Redvanly, C.S; Handbook of 
radiopharmaceuticals: Radiochemistry and applications; Wiley, 2005. 
 
Production of nitrogen-13 
There are several reactions leading to the production of nitrogen-13 (see Table 1.4). The 
generation of nitrogen-13 in cyclotrons has been focused in the production of the 
chemical specie [13N]NH4
+. This is a blood flow/perfusion marker and is used in cardiac 
studies to determine areas of ischemic or infarcted tissues.11 In this case, nitrogen-13 
can be generated by bombarding mixtures of water/ethanol with high energy protons 
(16O(p, α)13N nuclear reaction).12 The function of ethanol as a scavenger and reducing 
agent increases the amount of radioactivity generated as well as the relative amount of 
[13N]NH4
+ with respect to [13N]NO2
- and [13N]NO3
-. In the absence of this scavenger, 
the relative amount of [13N]NH4
+ decreases drastically to <20%.13 This is sometimes 
interesting in order to obtain [13N]NO2
- and [13N]NO3





Nuclear reaction Useful Energy Range (MeV) % Natural Abundance 
13C(p,n)13N 4-9 1.1 
12C(d,n)13N 1-6 98.9 
16O(p, α)13N 8-15 99.8 
10B(α,n)13N 4-6 19.9 
11B(α,2n)13N 6-10 80.1 
14N(p,pn)13N 14-30 99.6 
Table 1.4: Nuclear reactions used for obtaining nitrogen-13. Natural abundance refers to the irradiated 
stable isotope for the production of 13N. Obtained from: Welch, M.J; Redvanly, C.S; Handbook of 
radiopharmaceuticals: Radiochemistry and applications; Wiley, 2005.  
 
Production of oxygen-15 
There are several nuclear reactions for the production of oxygen-15 (see Table 1.5).  
Nuclear reaction Useful Energy Range (MeV) % Natural Abundance 
16O(p,pn)15O 20-26.5 99.8 
15N(p,n)15O 4-10 0.4 
14N(d, n)15O 2-10 99.6 
12C(4He,n)15O 12-18 98.9 
Table 1.5: Nuclear reactions used for obtaining oxygen-15. Natural abundance refers to the irradiated 
stable isotope for the production of 15O. Obtained from: Welch, M.J; Redvanly, C.S; Handbook of 
radiopharmaceuticals: Radiochemistry and applications; Wiley, 2005. 
 
The most commonly used reaction is 14N(d, n)15O; in this case, N2/O2 mixtures are 
irradiated with high energy protons. When these mixtures of nitrogen and oxygen are 
bombarded, nitrogen oxides can be produced directly, but [15O]O2 is the most abundant 
specie. Further reaction with hydrogen under catalytic conditions (e.g., palladium) 




Production of non conventional isotopes 
In the recent years, especial targets have been developed to be coupled to commercially 
available cyclotrons for the production of non conventional isotopes. Thus, solid 
materials (generally metals or metal oxides) can be irradiated with protons whose 
energy can be modulated by introducing energy degraders. Some examples of the 
production of non conventional positron emitters are shown in Table 1.6. 
Isotope Nuclear reaction  Max. energy (MeV) 
124I 124Te(p, n)124I 2.15 
86Y 86Sr(p, n)86Y 3.15 
64Cu 64Ni(p, n)64Cu 0.66 
45Ti 45Sc(p, n)45Ti 1.04 
89Zr 89Y(p, n)89Zr 0.90 
Table 1.6: Nuclear reactions used for obtaining non conventional positron emitters. Obtained from: 
Welch, M.J; Redvanly, C.S; Handbook of radiopharmaceuticals: Radiochemistry and applications; Wiley, 
2005. 
 
As can be seen, there are many alternatives for the selection of the radioisotopes, the 
way to generate them and the chemical form in which they can be obtained. However, 
efforts are focused nowadays towards the optimization of the existing methods for the 
generation of the most widely used radioactive precursors. 
1.1.4. The concept of radiotracer 
A radiotracer can be defined as a substance containing a radioactive atom to allow 
easier detection and measurement. The radioactive atom defines the physical properties 
of the radiotracer, while the chemical structure of the molecule attached to the 
radioisotope defines the biological properties of this radiotracer. Radiotracers have 
many applications, but their applicability is especially relevant in drug development and 
evaluation of response to specific therapies.15  
Many drugs fail in development stages due to unfavorable pharmacokinetic properties. 
They do not reach their target organ because of poor absorption and membrane 
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permeability, or because they are rapidly excreted so that the total exposure time is too 
short to achieve reasonable plasma level, or they are rapidly metabolized to a 
pharmacologically inactive metabolite. Because of these, it is obvious that detailed 
knowledge on the drug biodistribution is of key importance in the development of novel 
therapeutic and diagnostic tools. 
In experimental animals, such as mice and rats, studies on drug distributions are 
commonly carried out using whole-body autoradiography. The desired labeled 
compound is administered to animals which are sacrificed at different time points 
following compound administration. Autoradiography is quantitative and provides high 
spatial resolution and high sensitivity, but it has two principal drawbacks: i) drug 
distribution can only be assessed postmortem and ii) the method does not provide any 
information on drug metabolism because it is not possible to know if the radioactive 
group is bound to the parent compound or not. While this ex vivo technique provides 
valuable information about the pharmacokinetic properties of the drug, in vivo 
techniques allow obtaining information about absorption, distribution, metabolism and 
elimination (ADME). Consequently, there is an increasing realization that radiotracer 
drug imaging, mainly with PET, has a major role in drug development both in clinical 
and preclinical scenarios, which may reduce the substantial costs currently incurred.  
The use of the appropriate ligands for molecular imaging with PET will depend on the 
development of adequate tracers and efficient procedures for their radiolabeling. In the 
ideal situation, radiotracers interact only with the target molecule of interest and no non-
specific accumulation is observed. However, the ideal radiopharmaceutical does not 
exist. Some common criteria, not dependent on the PET application of the radiotracer, 
are:  
 High affinity for its target (low Kd). This characteristic allows obtaining high-
contrast PET images. The main mechanism of the radiotracer should be the 
accumulation in the target tissue. The required affinity depends on the 
concentration of the target. 
 High specificity. It is necessary because interaction of the radiotracer with other 
types of molecules will interfere with the desired radioactive signal detected by 
the PET camera. 
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 “Easy” radiolabeling. The radiolabeling procedure needs to generate a 
radiotracer with a good radiochemical yield. There are some parameters that 
should be considered, including position to be labeled, reaction time, choice of 
radioisotope and specific radioactivity. 
 Rapid metabolism of the radiotracer is not desirable. Labeled metabolites can 
bind to other molecules or play a role in unknown biochemical processes and the 
final result is a non-specific accumulation of the radioactivity.  
 Lipophilicity of the radiotracer. This parameter has an important relevance 
because it determines the ability of the molecule to cross cell membranes and 
barriers like blood-brain-barrier (BBB). The lipophilicity is usually expressed as 
the partition coefficient between n-octanol and water (log P). Log P > 1.5-2 is 
needed to cross lipid bilayers. Higher values (> 3) cause a high non-specific 
binding and hydrophobic interactions with lipids and proteins are provoked. 
Sometimes, the presence of carrier systems to help in crossing the cell 
membrane or other barriers is beneficial to obtain increased levels of the tracer 
in the cell, which means a higher contrast in images. 
 Clearance of non-specifically bound radioactivity in the time scale of 
measurement for PET is necessary to distinguish between specific and non-
specific uptake. 
 Low toxicity. Although small amounts of mass are injected (usually in the 
microgram scale), in most countries the authorities require toxicity tests in 
rodents and Ames test16 for mutagenicity using doses 1000-10000 times higher 
than PET doses.17,18 
1.1.4.1. Important considerations related to radiotracers 
Half-life of the radionuclide 
An important consideration in the production of PET radiotracers is the half-life of the 
radionuclide. Ideally, a radiotracer should be produced within 2-3 half-lives of the 
radionuclide to maintain high radiochemical yield and specific radioactivity. In addition, 
due to the low mass of radioactive agent, the stoichiometrical ratio between the non-
radioactive starting material (precursor for labeling) and the radioactive precursor is 
usually chosen in the range between 10000 and 10. As a consequence, the starting 
20 
 
radiolabeled reagent is consumed fast because of pseudo-first order reaction kinetics, 
independently of its concentration.  
Specific radioactivity 
The specific radioactivity can be defined as the ratio between the labeled and the non 
labeled compound. Although theoretical specific radioactivity values for PET isotopes 
are very high (see Table 1.7) these values are usually very far (10-10000 times higher) 
from specific radioactivity values obtained once the radiotracer has been synthesized. 
This decrease in specific radioactivity is due to a dilution process with the non 
radioactive isotope, usually occurring during radionuclide production and/or 
manipulation and preparation of the radiotracer. When this dilution process is 
significant and specific radioactivity is far from the theoretical value, the physical decay 
of the radionuclide does not only reduce the activity of the radiolabeled compound but 
also reduces the specific radioactivity by a factor 2 for every half-life. Thus, specific 
radioactivity of a radiotracer decreases with time.  
Nuclide 






Table 1.7: Theoretical specific radioactivities for some 
radioisotopes. Obtained from: Welch, M.J; Redvanly, C.S; 
Handbook of radiopharmaceuticals: Radiochemistry and 
applications; Wiley, 2005. 
 
Recent advances in PET applications are associated to an increasing demand for novel 
and specific radiotracers labeled, mainly, with carbon-11 and fluorine-18, and in some 
applications, such as the study of the behavior of bioactive or toxic molecules, dose 
exposure studies and the visualization of low density receptors in the brain, the concept 
of specific radioactivity becomes especially relevant because the total quantity of tracer 
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administered (labeled + unlabeled) is related to the specific radioactivity and the amount 
of radioactivity injected.  
The competition between the labeled and the unlabeled compounds may have a negative 
effect on the concentration of the radioactivity in the target tissue, and it can definitely 
produce undesired pharmacodynamic and/or toxic effects, as well as receptors 
saturation. Hence, a high specific activity should provide a sufficient contrast in images 
between the target tissue and its surrounding. In addition, in the case of dosimetry 
studies, a selective use of different specific radioactivity values can help in finding an 
optimal value.19,20  
Importantly, specific radioactivity can be always reduced by diluting the radiotracer 
with non radioactive compound, while it cannot be increased. Thus, synthesis 
procedures yielding high specific radioactivity values permit the preparation of the 
radiotracer with a pre-determined specific radioactivity by simple addition of the right 
amount of non labeled specie.   
Specific radioactivity values of cyclotron produced radioisotopes are usually dependent 
on several factors: the material they are in contact with during irradiation and transfer to 
the synthesis module, the quality of the irradiated material and the amount of 
radioactivity produced during irradiation. Stable isotopes leaking from the surface of 
target holder and/or tubings, or present in the irradiated material, may thus contaminate 
the radionuclides, thereby reducing the specific activity.21  
The synthetic process followed for the preparation of the radiotracers has also an 
important impact in the specific radioactivity. In the particular case of carbon-11, 
competing side reactions with environmental carbon-12 sources (especially when 
[11C]CO2 is used as radioactive precursor) and its short half-life make high specific 
activity radiotracers labeled with carbon-11 some of the most synthetically challenging 







Drug development is a long (10-15 years), complex and expensive process (the average 
costs is around 1 billion $). The US Food and Drug Administration (FDA) estimates 
that a drug entering in a clinical trial today has only 8% possibilities of reaching the 
market.  
The sensitivity of PET makes the detection of radiotracers at concentrations in the low 
picomolar range possible (which means that the total amount of radiotracer 
administered is typically less than 1 µg). The potential toxicological risk to humans at 
this mass scale is very limited. These PET studies in which tiny amounts of radiotracer 
are used are known as PET microdosing studies, Phase 0 clinical trials or First-time-in-
humans. Accelerator mass spectrometry (AMS) is another technique based on the 
administration of radiotracers that is suitable for microdosing studies. Microdosing 
studies have no therapeutic or diagnostic purpose but they establish whether a novel 
compound has appropriate pharmacokinetic and pharmacodynamic profiles in humans, 
which means that they evaluate the administration, distribution, metabolism and 
elimination (ADME) and/or distribution properties or receptor selectivity profile 
(pharmacodynamic endpoint) of new drugs earlier in the development process of a 
novel drug and at the same time of the preclinical stage, which could be a major 
advantage in the design and decision concerning clinical development of an agent.22 
The Committee for Human Medicinal Products (CHMP) of the European Agency for 
the Evaluation of Medicinal Products (EMEA) defined microdose as the dose of one-
hundredth (1/100th) of the pharmacologically active dose (up to a maximum of 100 µg, 
or 30 nmol for protein products). Preclinical toxicology studies should demonstrate that 
a dose 100 times the proposed human dose does not induce adverse effects. These 
toxicological studies required in animals in order to do a microdose study are extended 
single-dose studies in only one appropriate mammalian specie with a control group, 
with comparative in vitro data. 23 
Microdosing appears to be adequate for compounds (small organic molecules, peptide 
and protein therapeutics) with linear pharmacokinetics, small molecules with short half-
lives or compounds that are metabolized and have a rapid dissociation of binding to 
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their target. In contrast, microdosing is not appropriate for molecules with nonlinear 
pharmacokinetics and/or high-affinity binding to their targets. 
One of the ideal isotopes to perform microdosing studies is carbon-11, because the 
radiotracer can be prepared with the same chemical structure as the compound under 
evaluation. Moreover, its short half-life enables to repeat studies on the same subject 
within the same day. It is therefore possible to measure the baseline and effect of drug 
treatment on receptor occupancy in the same subject on the same day, thereby 
eliminating inter-subject variability and facilitating conclusive studies in a limited 
number of volunteers.24,25 
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1.2. LABELING STRATEGIES FOR SHORT LIVED ISOTOPES 
1.2.1. General Aspects 
Radiolabeling is the chemical reaction in which the radionuclide is incorporated in the 
desired molecule to yield the radiotracer (Figure 1.7). Many synthetic routes to prepare 
PET radiotracers have been developed during the last decades. Mainly, developed 
radiotracers incorporate carbon-11 and fluorine-18; the radioactive atoms are 
incorporated in the target molecules by organic chemical reactions, usually in organic 
solvents. The half-lives of nitrogen-13 and oxygen-15 are too short to perform 
radiochemical syntheses of more than one reaction step, and thus the number of 






Figure 1.7: General process for the production of a radiotracer. The non radioactive precursor usually has 
an active center (with a good leaving group, triangle in the figure) while all other reactive groups are 
protected (circles in the figure). The radioisotope (star in the figure) is introduced in a first step. After 
reaction, the protective groups are removed to yield the desired radiotracer. 
In some cases, before the radiolabeling step, it is necessary to protect reactive groups of 
the target molecule to avoid the introduction of the radioisotope at unwanted positions 
or to avoid negative effects of some functional groups on the labeling efficiency. In this 
case, the process requires a deprotection step after the labeling for removal of the 
protecting groups. Due to the short half-life of PET radionuclides, methods to increase 
the radiochemical yields and/or allowing shorter reaction times have been developed 
such as microwave assisted reactions and microfluidics technology.  
In a basic research radiochemistry laboratory, where the main focus is the development 
of new labeled species, versatility of the equipment and the capacity to implement new 
synthesis strategies is very important. In contrast, the production of large scale 








robust processes in mono-dedicated synthesis modules (to avoid cross contamination), 
linked to high capacity cyclotrons and targets. To avoid cross contamination and reduce 
preparation time, routine production of PET radiopharmaceuticals for clinical use is 
increasingly performed using single use kits which contain all the necessary reagents 
and solvents. 
1.2.2. Radiochemistry with fluorine-18 
The main advantage of fluorine-18 is its half-life (109.8 min), which allows longer 
synthesis routes than other radioisotopes. Moreover, distribution of the radiotracers 
from high-scale production centers to surrounding hospitals is feasible.  
Most used reactions with [18F]F- (no-carrier-added) involve SN2 reactions in aliphatic 
compounds and SNAr reactions in homo-aromatic and hetero-aromatic compounds with 
a suitable leaving group. Electrophilic substitution reactions using [18F]F2 can also be 
applied but, in this case, final radiotracers have low specific radioactivity. Electrophilic 
substitution reactions include additions across double bonds, reactions with carbanions 
and fluorodehydrogenation and fluorodemetallation. 
1.2.2.1. Nucleophilic fluorination 
Nucleophilic fluorination allows obtaining a large variety of radiotracers with high 
radiochemical yields and high specific radioactivities. There are two main options to 
perform nucleophilic fluorinations: 
 Direct substitution of an appropriate leaving group by [18F]F- in the desired 
precursor, which can be followed by hydrolysis of protective groups. 
 Preparation of an intermediate fluorinating agent by nucleophilic substitution, 
followed by a second reaction to finally perform a deprotection step. 
After the production of [18F]F- in the cyclotron, the [18F]F- anion is in aqueous solution; 
under these conditions, [18F]F- is a poor nucleophile but a strong base. In order to isolate 
[18F]F-, it is  trapped in an anion exchange resin contained in a cartridge, previously 
conditioned with K2CO3 or other potassium salts, like KHCO3 (when the decrease of the 
basicity for the reaction medium is required) to improve trapping yields (>95%). In this 
step, K[18F] is formed, which is not soluble in organic polar non protic solvents 
(suitable for SN2 reactions). Because of the lack of solubility, a phase-transfer catalyst is 
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needed, such as tetraalkylammonium salts or aminopolyethers. In addition, a few (2-3) 
azeotropic evaporations with dry acetonitrile are performed to remove any trace of 
water, which could decrease the nucleophilicity of the anion. 1,2 
Once [18F]F- has been isolated, a solution of the precursor in a polar, non protic solvent 
is added and the reaction mixture is usually heated (10-30 min, 80-160ºC). Typical 
solvents are acetonitrile, dimethyl sulfoxide (DMSO) and dimethyl formamide (DMF), 
although tertiary alcohols or amyl alcohols have been recently used with promising 
results.3 The advantage of using acetonitrile as the solvent is that it is easily removed by 
evaporation. On the other side, DMSO and DMF allow the reaction to take place at high 
temperature in closed reactors at low pressure. The use of microwave ovens is gaining 
relevance in fluorine radiochemistry, because shorter reactions times lead to higher 
yields with limited formation of undesired byproducts. 
Regarding the precursor, in aliphatic substitutions sulfonic esters such as triflates, 
tosylates, mesylates and nosylates are suitable leaving groups. Sometimes bromide or 
iodide are used, but lower radiochemical yields are obtained. Aromatic substitutions 
need to be carried out with electron-withdrawing groups (nitro- or trimethylammonium) 
in the para or ortho position of the substituted moiety.4 
The most widely used nucleophilic reaction for the incorporation of fluorine-18 into a 
precursor to yield a radiotracer is applied to the production of [18F]FDG. The reaction 





































Scheme 1.1: Synthesis of [18F]FDG. Mannose triflate reacts with [18F]F- in acetonitrile. After fluorination 
is completed, the protective groups (acetyl) are eliminated by hydrolysis under acidic or basic conditions. 
Adapted from: Dollé, F; Roeda, D; Kuhnast, B; Lasne, M.C; Fluorine and Health, Elsevier, 2008.   
1.2.2.2. Electrophilic fluorination 
In electrophilic fluorinations, fluorine is reacted with an electron-donating reactant such 
as an alkene, aromatic ring or carbanion to form a carbon-fluorine covalent bond. 
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Possible electrophilic fluorinations include additions to double bonds or electrophilic 
aromatic substitutions of a trialkyl tin or mercury group. The synthetic procedure is 
simple and involves bubbling of the gas into the substrate solution. Taking into account 
the extremely high reactivity of F2 and, consequently, the difficulties associated to 
[18F]F2 production, electrophilic fluorinations are not used very often. The oxidizing 
strength of fluorine often leads to exothermic radical chain reactions with the formation 
of side products. It was found that its reactivity could be moderated by dilution with an 
inert gas and by performing the reaction in a strong acidic medium.5,6  
One of the most important electrophilic fluorinations in radiochemistry is the 
preparation of [18F]FDOPA,7 radiotracer used for studying the presynaptic dopamine 
metabolism, for example in the diagnostic of Parkinson disease. The synthesis pathway 
is following a direct electrophilic substitution of the stannyl precursor, followed by acid 
hydrolysis of the protection groups and purification by HPLC. The synthesis pathway is 

















1. [18F]F2 / CHCl3
2. HCl
 
Scheme 1.2: Synthesis of [18F]FDOPA. The stannyl precursor is reacted with [18F]F2 in 
CHCl3 and then the protective groups are eliminated by hydrolysis under acid 
conditions. The reaction crude is purified by HPLC. 
1.2.2.3. Other fluorination  strategies 
Indirect [18F]fluorination with suitable prosthetic groups is an interesting alternative to 
nucleophilic and electrophilic substitutions, because reactions can be usually performed 
under mild conditions limiting thus, the formation of byproducts.  
One recently developed strategy is the so called click chemistry, or formation of triazole 
rings by the cycloaddition of alkynes to azides (Scheme 1.3). This reaction has been 
exploited in radiochemistry due to the speed, selectivity and simplicity under mild 
reaction conditions. A possible limitation of this method is that copper catalyst can 
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decompose under acidic conditions. Furthermore, the biological effect of including 















Cu, DIPEA, Na ascorbate
 
Scheme 1.3: Example of a click reaction in radiochemistry for the introduction of a 18F atom into a 
peptide. Obtained from: Miller, P.W; Long, N.J; Vilar, R; Gee, A.D; Synthesis of 11C, 18F, 15O and 13N 
Radiolabels for positron emission tomography, Angew. Chem.; 2008, 47: 8998-9033. 
 
Another strategy consists of using enzymes for the introduction of the radioactive label. 
This is also an attractive strategy because enzymatic reactions are specific. However, 
this approach is more used in carbon-11 chemistry.8 
1.2.3. Radiochemistry with oxygen-15 
Due to its short half-life, oxygen-15 is not commonly used in PET applications.Its short 
half-life is an important drawback to perform radiochemical syntheses including more 
than one reaction step. Simple chemical products such as [15O]CO2 and [
15O]O2 can be 
obtained directly from the cyclotron and used without further reaction or purification 




















14N(d,n) 15O 16O(p,pn) 15O
 
Scheme 1.4: Synthesis of common oxygen-15 compounds for PET 
applications. Obtained from: Miller, P.W; Long, N.J; Vilar, R; Gee, 
A.D; Synthesis of 11C, 18F, 15O and 13N Radiolabels for positron 




[15O]H2O can be also synthesized in an on-line process with high efficiency. Some 
alcohols (see Scheme 1.4) have been also prepared by direct reaction of [15O]O2 with 
trialkyl boranes.9 
1.2.4. Radiochemistry with carbon-11 
Carbon-11 is the radioisotope with a wider range of reported labeling strategies. It can 
be obtained in commercially available cyclotrons as [11C]CO2 and [
11C]CH4, and one of 
the simplest labeling strategies consists of performing Grignard-type reactions by using 
[11C]CO2. However, very often, the radioactive specie generated in the cyclotron (either 
[11C]CO2 or [
11C]CH4) is converted into a more suitable specie for further reaction with 
the adequate precursor. The variety of reactions that can be made from these precursors 


































Scheme 1.5: Most important 11C precursors used in the synthesis of 11C-labeled compounds produced 
from either [11C]CO2 or [
11C]CH4. Obtained from: Miller, P.W; Long, N.J; Vilar, R; Gee, A.D; Synthesis 
of 11C, 18F, 15O and 13N Radiolabels for positron emission tomography, Angew. Chem.; 2008, 47: 8998-
9033. 
 
1.2.4.1. Methyl Iodide as methylating agent 
Production of [11C]CH3I and direct methylations 
The most commonly used radioactive precursor for introducing carbon-11 into organic 
molecules is, by far, [11C]CH3I; with this radioactive precursor, a methylation reaction 
is performed in order to incorporate [11C]CH3- into the target molecule. This 
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[11C]methylating agent can be prepared by the “wet” method10 or by the gas-phase 
reaction.11 The “wet” method starts with the transformation of [11C]CO2 into 
[11C]CH3OH via reduction with LiAlH4 and a final iodination with hydriodic acid 
(Scheme 1.6). These steps can be easily carried out, but some precautionary measures 
should be taken. After the trapping of [11C]CO2 in LiAlH4, the solvent (tetrahydrofuran, 
THF) should be removed using vacuum, inert gas flow and heat. Later, the aluminium 
salt must be cooled again in order to add concentrated hydriodic acid without producing 
an exotermic reaction. Once HI has been added, the mixture is again heated to distill 
[11C]CH3I using an inert gas stream. The main difficulty is to maintain the specific 
activity of the radioactive precursor as high as possible. This is especially critical in the 
manipulation of LiAlH4. Attention should be paid also in maintaining inert atmosphere 













Scheme 1.6: Schematic pathway for the production of [11C]CH3I from [
11C]CO2. 
An alternative strategy for obtaining high specific activity values is the use of [11C]CH4 
instead of [11C]CO2 in the synthesis of the [
11C]methylating agent [11C]CH3I. The 
amount of CH4 in the atmosphere is considerably lower than the amount of CO2 and 
thus the contamination is strongly restricted. When [11C]CH4 is obtained from the 
cyclotron, a gas-solid iodination reaction of [11C]CH4 at high temperature provides 
[11C]CH3I as [
11C]methylating agent. The iodination step is carried out in a quartz tube 
which contains I2 vapor at 720 ºC. The high temperature allows the dissociation of 
iodine molecule and the reaction with the [11C]CH4 (see Scheme 1.7).
12 The 
disadvantage of this methodology is the low efficiency in the radical reaction, so the gas 









Scheme 1.7: Schematic pathway for the production 




When methylation using [11C]CH3I is slow, [
11C]methyl triflate can be used to obtain 
better radiochemical yields in milder conditions, due to its higher reactivity. [11C]methyl 
triflate is prepared by passing gaseous [11C]methyl iodide (either prepared by the “wet” 
or the “gas-phase” method) through a silver triflate column at high temperature.13 Other 
alkylating agents have been developed, such as [11C]ethyl iodide, [11C]propyl iodide, 
[11C]butyl iodide and [11C]benzyl iodide,14 although reactions are usually slower due to 
steric hindrance.  
Methylation reactions including [11C]CH3I or [
11C]CH3OTf are nucleophilic 
substitutions of methyl iodide with a precursor, usually an amine, alcohol or thiol group. 
The simplicity and the short reaction times that this step requires have converted this 
strategy into one of the most commonly used for the production of 11C-labeled 
compounds. 
The development of captive solvent methods, where the radioactive synthon is trapped 
in a solution of the non radioactive precursor, is a clear example. Automated continuous 
flow reaction and purification systems using narrow-bore stainless-steel or 
plastic/polymer loops as reactors have found an increased use in simple 
[11C]methylation reactions because their ease use and versatility. These methods are 
called “in loop” methods, and they involve coating the inside surface of the loop with 
micromolar amounts of non radioactive precursor in a suitable solvent and then passing 
a gaseous stream of [11C]CH3I or [
11C]CH3OTf through the loop.  
These methods have been used to label a large variety of biological compounds due to 
their good radiochemical yields, purities and their short reaction times.15 The efficiency 
of this methodology is excellent, taking into account that surface areas of the reaction 
loops are relatively small and the fact that they can be carried out without cooling or 
heating the system. Another advantage is that the loop minimizes the use of solvents 
and precursor material which may contribute to the increased efficiency of the reactions. 
In addition, minimal losses of labeled product occur as a result of transfers because the 
crude reaction mixture can be introduced directly into an integrated HPLC system for 
purification or, even better, in a cartridge to perform purification through a solid-phase 
support.16 A typical methylation reaction for the production of [11C]raclopride, which 
can be carried out by using the captive solvent method, is shown in Scheme 1.8.  
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Indirect [11C]methylation strategies using [11C]CH3I and [
11C]CH3Otf have been also 
developed. One example is the preparation of [11C]dimethylamine as intermediate, 
which can be used for the preparation of [11C]methylated compounds with 
dimethylamine functional groups. Although direct labeling using [11C]CH3I can be 
achieved, an indirect method using [11C]dimethylamine and bromide precursors shows 
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Scheme 1.8: Synthesis of [11C]raclopride. The non radioactive precursor is reacted with 




















Scheme 1.9: Radiosynthesis of [11C]dimethylamine and reaction with bromomethyl-4-nitrobenzene to 
yield the 11C-labeled radiotracer. Obtained from: Miller, P.W; Long, N.J; Vilar, R; Gee, A.D; Synthesis of 
11C, 18F, 15O and 13N Radiolabels for positron emission tomography, Angew. Chem.; 2008, 47: 8998-9033. 
 
Another strategy to achieve the [11C]methylation is the so-called “safety-catch” linker 
method (Scheme 1.10). This method is based in using a solid-support, like polymers, to 
carry out reactions. The precursor is attached to a solid support and then treated with the 
radiolabeling agent. The unlabeled compound remains with the polymer and thus 
simplifies purification. Most commonly used resins include REM and Kenner.18 
The “safety-catch” process provides high purity 11C-labeled compounds avoiding HPLC 
purification. Moreover, the method is based on standard combinatorial synthesis and 
































Scheme 1.10: 11C-methylation of the resin-attached precursor molecule followed by release of the labeled 
molecule under basic conditions. Obtained from: Miller, P.W; Long, N.J; Vilar, R; Gee, A.D; Synthesis 




In the last decades, many groups have developed a large number of reaction strategies 
for the formation of C-C, C-O and C-N bonds via palladium-catalyzed reactions. These 
strategies have been applied to the preparation of 11C-labeled compounds, although, in 
the radiochemistry scientific community, the commonly accepted term for this kind of 
reactions is “palladium-mediated reaction” instead of “palladium-catalyzed reaction” 
due to the excess of palladium complex compared to the amount of radioactive 
precursor. Stille-type reaction has been the most widely used (Scheme 1.11).19 The use 
of stannanes is compatible with many functional groups while the polarity of the 
molecule is not very high, helping in the purification step via chromatographic 
separation. One important drawback of using stannanes is the toxicity, which may cause 
problems for in vivo studies. Another well studied palladium-mediated reaction in 
radiochemistry is the Suzuki method, which has higher radiochemical yields than the 











Scheme 1.11: Stille cross-coupling reaction for the formation of 11C-labeled alkenes using [11C]CH3I. 
Obtained from: Miller, P.W; Long, N.J; Vilar, R; Gee, A.D; Synthesis of 11C, 18F, 15O and 13N 




1.2.4.2. Grignard reactions 
As stated before, [11C]CO2 can be used directly after obtention from the cyclotron by 
reacting with organometallic Grignard reagents to form [11C]carboxymagnesium halides 
and then transformed into the [11C]carboxylic acids. These can be converted into more 
reactive species (e.g., acid chloride) and react with amines to form [carbonyl-
11C]amides and  [11C]ureas.21 An important example of the applicability of this 
synthethic strategy is found in the preparation of [11C]acetate, a radiotracer used in the 













Scheme 1.12: Schematic pathway of [11C]acetate synthesis. 
1.2.4.3. [11C]carbonylation reactions 
The interest in labeling molecules with [11C]CO is due to two main reasons: (i) the wide 
variety of carbonyl-containing biologically interesting molecules which can be 
synthesized through carbonylation reactions and (ii) the possibility to obtain [11C]CO 
through the reduction of [11C]CO2 over zinc or molybdenum in an on-line process. The 
most widely used method is the palladium-mediated [11C]carbonylation process.23 
Carboxylic acids,24 esters,25 amides26 and imides27 are some of the products which can 
be synthesized via palladium-mediated carbonylation of olefins, alkynes and organic 
halides using carbon monoxide at atmospheric pressure. 
The catalytic cycle consists of three steps: (i) oxidative addition of the organohalide to 
Pd0, (ii) insertion of [11C]CO into the carbon-palladium bond and (iii) nucleophilic 
attack on the carbonyl carbon and reductive elimination (Scheme 1.13).  
The limited use of [11C]CO as radioactive precursor in the insertion of carbon-11 is due 
to the poor reactivity of carbon monoxide as a result of its low solubility in organic 
solvents at low CO pressures. Recently, different strategies to improve [11C]CO 




























Scheme 1.13: Mechanism of palladium-catalyzed carbonylation of organohalides.  
 
1.2.4.4. Other reactions for the incorporation of carbon-11 
Although [11C]alkylation by using [11C]alkyl iodide or triflate and palladium-mediated 
reactions (either for the introduction of [11C]CO or [11C]CH3-) and Grignard reactions 
using [11C]CO2 are by far the most commonly used strategies for the preparation of 
11C-
labeled radiotracers, other synthetic routes have been also used with interesting potential 
applications. [11C]phosgene has been developed as a synthon for 11C-labeling;29 
although it is a very reactive specie which could be applied for fast and efficient 
incorporation of carbon-11 into molecules, there are still technical difficulties regarding 
its production in a reliable and reproducible way. Another radioactive precursor is 
[11C]HCN, which is the starting material for [11C]cyanation reactions and it is usually 
prepared by the reduction of [11C]CO2 to [
11C]CH4 using H2 over nickel, and further 
conversion into [11C]HCN by reaction with NH3 over platinum.
30 [11C]HCN can be used 
directly or may be converted into [11C]CuCN to react with aryl halides (Scheme 1.14) 

















































Scheme 1.14: Summary of [11C]cyanation reactions. Obtained from: Miller, P.W; Long, N.J; Vilar, R; 
Gee, A.D; Synthesis of 11C, 18F, 15O and 13N Radiolabels for positron emission tomography, Angew. 
Chem.; 2008, 47: 8998-9033. 
 
1.2.5. Radiochemistry with nitrogen-13 
As in the case of oxygen-15, nitrogen-13 is an attractive radionuclide for labeling 
biomolecules because their stable isotopes (oxygen-16 and nitrogen-14, respectively) 
are in large variety of bioactive molecules. However, the extremely short half-life of 
nitrogen-13 (9.98 min) has imposed limitations in the radiosynthesis of labeled species 
and putative clinical application; on the other hand, the development of 13N-labeled 
radiotracers would allow performing repeated PET procedures on the same subject 
within one day due to the fast decay. 
Nowadays, main applications of nitrogen-13 include: (i) direct use as [13N]NH4
+ to 
measure myocardial blood flow32 and (ii) production of 13N-labeled amino acids. 
Actually, an extensive range of 13N-labeled aminoacids have been prepared (Table 1.8) 





N-labeled amino acid Precursor 
13
N reagent Enzyme 
L-[13N]alanine Pyruvate [13N]NH3 GAD
33 
L-[13N]leucine α-ketoisocaprate [13N]NH3 GAD
34 
L-[13N]methionine α-keto-γ-methiol-butyrate [13N]NH3 GAD
34
 
L-[13N]Phenylalanine Phenylpiruvate [13N]NH3 PAD
35 
L-[13N]Tyrosine p-hydroxy-phenylpiruvate [13N]NH3 PAD
35 
Table 1.8: Examples of 13N-labeled amino acids reported in the literature.  
These compounds are of particular interest for the determination of protein synthesis 
rates, particularly in tumors, and are usually produced through biosynthetic methods 
using enzymes, which enable rapid region and stereospecific syntheses to be performed 
under mild aqueous reaction conditions. 
Apart from the production of amino acids, nitrogen-13 has been also used for the 
production of other 13N-labeled species, such as amines. Several strategies have been 
used, like reaction via [13N]imines using [13N]ammonia as radioactive precursor,36 or 
the reaction of acid chlorides with [13N]ammonia to yield the corresponding amides, 
which are later reduced to the amines using LiAlH4 (Scheme 1.15).
37 Other routes for 













Scheme 1.15: Synthesis of [13N]-β-phenethylamine through the corresponding amide and reduction with 
LiAlH4. Adapted from: Tominaga, T.; Inoue, O.; Suzuki, K.; Yamasaki, T.; Hirobe, M.; Synthesis of 
13N-




Nitrogen-13 has been also used for the preparation of other 13N-labeled species, 
although literature reporting these works is not very extensive. N-nitrosoureas have 
been labeled with nitrogen-13 with moderate radiochemical yields starting from the 
radioactive precursor [13N]NO2
-, obtained from the reduction of [13N]NO3
-.39 This 
method was optimized later by using more concentrated carrier solutions to prepare 
antibiotics in good yields.40 More recently, a resin supported methodology for the 
preparation of 13N-labeled nitrosamines and 13N-labeled nitrosothiols was reported41 
although many details about the procedure were omitted and reaction conversions and 
radiochemical yields were not specified. 
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2.1. JUSTIFICATION OF THE WORK 
The scientific work carried out during this PhD thesis has been performed in two 
different centers. The first part was carried out at Institut d’Alta Tecnologia PRBB-
Fundación Privada (IAT-PRBB), while the second part was developed at CIC 
biomaGUNE. 
IAT-PRBB is a full profit company offering molecular imaging services based on 
Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI). The 
main goals of the company are: (i) to collaborate with industry and/or research groups 
offering knowledge and state-of-the-art equipment in the field of molecular imaging, to 
solve (using a multimodal approach) medical or biological questions using imaging 
technologies, and (ii) to produce [18F]FDG in a high scale fashion for self use in clinical 
applications and to be distributed to nearby hospitals. In this scenario, the 
radiochemistry department was involved in clinical (human) and pre-clinical 
(experimental animals, mainly rodents) trials, usually sponsored by pharmaceutical 
companies or, occasionally, by research groups. In these projects, efforts were not 
focused in the development of new labeled chemical entities, but in the development (or 
refinement) of protocols for the manufacture of known tracers using fast, efficient and 
reproducible processes in a GMP environment. 
In one of these above mentioned clinical trials, a large number of patients had to be 
scanned with L-[methyl-11C]methionine ([11C]methionine), a radiotracer used for the 
assessment of brain tumors when [18F]FDG is not appropriate (due to high uptake by 
normal brain tissue). Due to several reasons (specified in section 3.1), a method based 
on the captive solvent method had to be developed to produce [11C]methionine 
efficiently. The method should permit the production under GMP environment and the 
final radiotracer should accomplish specifications according to the Spanish 
Pharmacopoeia. From this work, the first paper entitled “New method for routine 
production of L-[methyl-
11
C]methionine: in loop synthesis” was published in Journal of 
Labelled Compounds and Radiopharmaceuticals. 
Also during this period, several clinical trials with new labeled chemical entities were 
started. Due to the relatively high toxicity of some of the radiotracers (which presented 
minor adverse effects even when administered in the microgram scale) specific 
radioactivity for radiotracers synthesized through the “wet” method became an issue. 
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With the aim of improving specific radioactivity and to find out which were the major 
sources of non radioactive carbon, a deep analysis of the different elements involved in 
the whole synthetic process was carried out. The second paper entitled “Specific activity 
of [
11
C]CH3I synthesized by the ‘‘wet’’ method: Main sources of non-radioactive 
carbon” was published in Applied Radiation and Isotopes as a result of this work. Using 
the results of this work, two more publications were prepared in which the process to 
obtain optimal specific radioactivity values was applied to the preparation of two 
tracers. These works have not been included in the compendium of the present PhD 
thesis but are attached as annexes (Annex I and II). 
CIC biomaGUNE, the center where the second part of this PhD thesis was developed, is 
a non-profit research organization created to promote basic scientific research and 
technological innovation. Thus, the main goals of the radiochemistry laboratory at CIC 
biomaGUNE are (i) the development of new imaging agents with potential applications 
in PET and SPECT and (ii) the development of new radioactive precursors with 
application in the manufacture of complex labeled structures.  
Taking advantage of prospective studies carried out by some members of our research 
group related to the preparation of 13N-labeled compounds, this work was continued and 
research was focused in the development of new labeling strategies for the production 
on 13N-labeled species. As it has been stated in the introduction, not much work has 
been published up to date related to the use of nitrogen-13 as labeling agent, although 
there is a great variety of biologically active compounds containing nitrogen in their 
structure. The possibility to label such compounds with a positron emitter would mean 
an excellent tool for giving further understanding of their specific biological and/or 
physiological role in vivo. 
Most of the work historically carried out with nitrogen-13 has been focused in the 
production and further use of [13N]NH4
+ as labeling agent. In the current PhD thesis, the 
work has been focused in increasing the variety of radioactive precursors containing 
nitrogen-13 and its automated and efficient production. Specifically, efforts have been 
oriented to improve the production of [13N]NO3
- and [13N]NO2
- and further application 
to the radiosynthesis of 13N-labeled nitrosothiols and nitrosamines. From this work, two 





N-GSNO) as a new potential PET imaging 
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agent” and “Fully automated synthesis of 
13
N-labeled nitrosothiols”, published in 
Applied Radiation and Isotopes and Tetrahedron Letters, respectively) and one paper 
regarding the synthesis of 13N-labeled nitrosamines (entitled “Efficient system for the 
preparation of [
13
N]labeled nitrosamines” published in Bioorganic and Medicinal 
Chemistry Letters) have been published. Very recently, a new strategy for the 
preparation of 13N-labeled azo compounds (with potential application as β-amiloyd 
imaging agents) has been developed. From this work, one paper (entittled “A convenient 
synthesis for the preparation of 
13
N-labeled azo compounds: A new route for the 
preparation of PET probes for in vivo amyloid imaging”) has been written and is ready 






The objectives of this PhD thesis are: 
1. To develop a synthetic strategy for the automated, robust and efficient 
production of L-[methyl-11C]methionine. 
2. To study the main sources of non-radioactive carbon in the production of 
[11C]CH3I through the “wet” method. 
3. To establish general guidelines for the optimization of specific radioactivity 
values in the production of 11C-labeled structures through methylation via the 
“wet” method. 
4. To develop a fast, efficient and reproducible method for the production of 
[13N]NO2
- from cyclotron generated [13N]NO3
-. 
5. To develop synthetic strategies for the synthesis of 13N-labeled nitrosothiols. 
6. To develop synthetic strategies for the synthesis of 13N-labeled nitrosamines. 
7. To develop synthetic strategies for the synthesis of 13N-labeled azo compounds. 
8. To design and implement an automatic remote controlled synthesis module for 
the production of 13N-labeled structures using [13N]NO2
- as radioactive 
































3.1. PAPER 1: IN LOOP SYNTHESIS OF L-[METHYL-11C]METHIONINE 
3.1.1. Introduction 
In many radiosynthesis with carbon-11, the radioactive precursor (as [11C]CH3I or 
[11C]CH3OTf) is introduced (via gas-phase) into the precursor solution. Many attempts 
to streamline the process have revolved around the idea of eliminating the traditional 
“solution in reaction vial”, where the [11C]precursor is distilled into a vessel containing 
solvent, precursor and base (or catalyst, when is needed). In this methodology, cooling 
of the reactor is usually required for trapping [11C]precursor. After that, the reactor has 
to be heated in order to perform the synthesis and finally the reaction is quenched. 
When HPLC is needed for purification, the vessel content has to be transferred to the 
HPLC system.1  
An innovative technique was described to avoid manual steps and changes of 
temperature in the reactor, as well as to avoid the need of transfering the reaction 
mixture from the vial to the purification system.2 This method is called captive solvent 
chemistry. The main objective was to develop a solid support to trap the [11C]precursor 
and the reagents together, eliminating the need of a reaction vessel with a septa and 
needles. In the captive solvent chemistry, reactions could be conveniently carried out in 
a thin tubing loop. Commonly, this tubing is directly attached to the HPLC injector for 
easy purification after reaction.  
In recent years, this technique has been implemented in the synthesis of a variety of 
PET radiotracers.3 This method has two important advantages: (i) good efficiency of 
[11C]CH3I trapping into the loop without cooling and (ii) rapid methylation reactions 
without heating.4 Until 2004, only DMF and DMSO had been reported as solvents for in 
loop methylation reactions. This fact is mainly due to: (i) [11C]methylation reaction is a 
nucleophilic substitution and polar aprotic solvents are suitable to carry out these 
reactions, and (ii) [11C]CH3I is distilled under an inert gas stream towards the reaction 
loop (pre-charged with a solution of the precursor) and the loop is open to the 
atmosphere during reaction. Thus, high boiling point solvents are anticipated to be ideal 
to prevent evaporation during [11C]CH3I trapping and reaction with the precursor. 
However, sometimes these solvents are not suitable for the radiosynthesis of some 
specific compounds, as reported by Klein and Holschbach 2001,5 since the sulfur atom 
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in DMSO is a nucleophilic center and the solvent itself may compete with the non-
radioactive precursor.  
In the particular case of the here reported work, the captive solvent method needed to be 
applied to the preparation of L-[methyl-11C]methionine (Scheme 3.1). L-[methyl-
11C]methionine is one of the most widely used amino acids to image brain tumors. In 
brain tumors, the BBB can be functionally altered resulting in an increase of active 
amino acid transport. With L-[methyl-11C]methionine, quantitative measurements of the 
specific biochemical properties of tumor cells (at cellular level) or alteration of the BBB 
may be obtained.6,7 Because of the important role of L-[methyl-11C]methionine in PET, 
different routine methods have been developed in order to achieve high reproducibility 
and to make easy its production and purification. First improvements were made by 
Pascali et al.,8 who published the possibility to synthesize this radiotracer in a C-18 
solid-phase extraction cartridge. More recently, Mitterhauser and co-workers9 reported 
an automated system avoiding HPLC purification, which considerably increased the 














Scheme 3.1: Schematic process for the synthesis of L-[methyl-11C]methionine. 
Three main reasons forced the application of the captive solvent method to the 
preparation of L-[methyl-11C]methionine: (i) a clinical trial consisting of obtaining brain 
scans in patients using this radiotracer, had to be carried out. In some occasions, several 
patients had to be scanned within one day; (ii) the only automated technology available 
in the IAT-PRBB radiochemistry laboratory was designed to run reactions in an HPLC 
loop, and (iii) the process used until that moment in the laboratory (semi-manual) 
followed the guidelines described in the Spanish Pharmacopoeia;10 thus the non 
radioactive precursor was dissolved in ethanol and the reaction was carried out in a 
reactor in the presence of a strong base. In this scenario, changing the reaction solvent 
could involve time consuming and a long and costly validation process, especially 
concerning the quality control assays for the final radiotracer. 
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With the aim of overcoming this full validation process, a new process for the 
production of L-[methyl-11C]methionine following the in loop synthesis and using 
ethanol as solvent was developed, although ethanol has a low boiling point and risk of 
evaporation during [11C]CH3I distillation was foreseen. 
3.1.2. Results and discussion 
In spite of the problems associated to the use of a solvent with low boiling point, a 
method in which [11C]CH3I was trapped successfully in a 2 mL stainless-steel loop 
filled with water/ethanol 1:1 could be developed. In a typical production, [11C]CH3I was 
produced in a Bioscan Module starting from [11C]CO2 generated in the cyclotron IBA 
18/9 via de nuclear reaction 14N(p,α)11C. [11C]CO2 was almost quantitatively trapped in 
a molecular sieve column and then released by heating into a lithium aluminium hydride 
solution (0.1 M in dry THF) to form the alumminum salt. After evaporation of the 
solvent, hydriodic acid (57% aqueous solution) was added. [11C]CH3OH was formed in 
this step, undergoing under heating [11C]CH3I which was distilled into the loop, 
previously charged with the precursor solution (1 mg L-homocysteine solved in 80 µL 
of 0.5 M sodium hydroxide solution in water/ethanol 1:1). After complete trapping of 
[11C]CH3I, the reaction was carried out in 1 min at room temperature. The purification 
step consisted of pushing the reconstituted final solution with 7.5 mL of physiologic 
saline solution through a C18 cartridge (where unreacted [11C]CH3I was trapped). 
Finally, sodium phosphate was added to neutralize sodium hydroxide. To perform the 
last step (purification and formulation) an automated module was designed and 
implemented (see Figure 2, Paper 1). 
The in loop method allowed the preparation of L-[methyl-11C]methionine with good 
radiochemical yield (38.4 ± 4.1 % EOS). Specific radioactivity values were 28.9 ± 12 
GBq/µmol EOS, and the fact that the reaction was carried out in low boiling point 
solvents did not decrease neither the yield nor the reproducibility of the reaction. 
Quality control confirmed the chemical and radiochemical purity of the radiotracer, and 
all analytical parameters were within the specifications of Spanish Pharmacopoeia. 
Surprisingly, ethanol concentration in the final radiotracer was lower than expected 
(1360 ± 270 mg/L), due to partial evaporation while [11C]CH3I was distilled. 
Enantiomeric purity was determined by chiral HPLC and was > 99% in all cases (Figure 




The reaction of [11C]CH3I (produced via the “wet” method) with a solution of the non 
radioactive precursor (L-homocysteine) in water/ethanol under basic conditions permits 
the synthesis of L-[methyl-11C]methionine in good radiochemical yields (38.4 ± 4.1%, 
EOS) in a fully automated process by using the captive solvent method. The simplicity 
of the process and the implementation of an adequate cleaning sequence between 
consecutive runs permits multiple productions within one day with minimal radiological 
exposure. 
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3.2. PAPER 2: IMPROVING SPECIFIC RADIOACTIVITY 
3.2.1. Introduction  
As it was reported in the paper entitled “New method for routine production of L-
[methyl-
11
C]methionine: in loop synthesis”, the captive solvent method is suitable for 
the production of  L-[methyl-11C]methionine with good radiochemical yields. This 
methodology was extended to the preparation of other 11C-labeled radiotracers which 
required purification by HPLC.  
However, and as can be seen in the results obtained in the previous work (Paper 1) 
relatively low values of specific radioactivity values (average of 28.9 ± 12 GBq/µmol, 
EOS) were obtained in the production of L-[methyl-11C]methionine, with total 
production time of 12 minutes. These values led to the conclusion that specific 
radioactivity (corrected to the end of bombardment) was 43.5 ± 18 GBq/µmol. Specific 
radioactivity of a radiotracer decreases as radioactivity does; thus, if production time is 
increased (e.g., due to the need of purification via HPLC, or longer reaction times due to 
less reactivity of the non radioactive precursor) specific radioactivity of the final 
radiotracer will decrease. With specific radioactivities around 40 GBq/µmol (EOB), the 
specific radioactivity of the radiotracer would be around 20, 10 and 5 GBq/µmol for 
production times of 20, 40 and 60 minutes, respectively.      
Specific radioactivity is not an issue in the particular case of L-[methyl-11C]methionine 
because it is a protein incorporation marker. However, this parameter becomes essential 
when receptor occupancy studies are carried out and/or when high toxicity molecules 
are used. The radiochemistry laboratory of IAT-PRBB was involved in two clinical 
studies in which specific radioactivity had special relevance:  
 The first clinical trial was related to striatal D2 receptor occupancy. In this study, 
the synthesis of [11C]raclopride (a radiotracer useful to determine the density of 
striatal dopamine D2 receptors) with reproducible and high specific radioactivity 
values was required.  
 The second clinical trial was a First Time in Humans assay. This study consisted 
of the implementation of a manufacturing procedure for the preparation of the 
recently developed GlyT-1 PET radioligand to be applied in: (i) quantification of 
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GlyT-1 density, (ii) determination of drug-induced receptor occupancy and (iii) 
elucidation of the role played by GlyT-1 in schizophrenia. Due to the already 
known toxicity of the radiotracer (minor adverse effects were observed at doses 
higher than 3 µg in humans), the specific activity became, again, an important 
parameter. 
As stated in the introduction (section 1.2.4.1) there are some alternatives to the “wet” 
method to produce high specific radioactivity 11C-labeled radiotracers. A well known 
procedure involves using [11C]CH4 as starting material instead of [
11C]CO2 to produce 
[11C]CH3I through the gas-phase method.
1 Nevertheless, the technology to run the 
reaction by using this methodology was not available in the IAT-PRBB laboratory, 
while a very well implemented system to produce [11C]CH3I by using the “wet” method 
had been implemented; thus, there was a need to search for the main sources of non 
radioactive CO2 in the production of  [
11C]CH3I via the “wet” method in our 
configuration with the aim of minimizing them and obtaining radiotracers with the best 
possible specific radioactivity.  
Although the “wet” method is, in general terms, the preferred method to perform 
[11C]methylation reactions (it is a well established reaction and offers good 
radiochemical yields) and the fact that increasing specific radioactivity is always highly 
desirable, from the early 1980s only a few works have evaluated the factors that 
potentially affect the presence of the non-radioactive specie, and there are still some 
controversial about the sources of non-radioactive carbon. Iwata et al.2 concluded that 
carbon-12 comes from THF traces after the evaporation step. However, Zhang and 
Suzuki3 pointed towards the LiAlH4 solution as a main source of carbon-12, while 
Matarrase et al.4 asserted that the major contribution comes from the [11C]CO2 
production in the cyclotron. These differences suggest that the sources of contamination 
are extremely dependent on each particular configuration (cyclotron and targets, transfer 
lines, synthesis module, synthesis protocol, etc.) which differs from site to site.   
3.2.2. Results and discussion 
With the aim of minimizing the sources of non-radioactive carbon in the particular 
configuration of IAT-PRBB, we planned different experiments were planned in order to 
assess the contribution of each individual element to the final amount of unlabeled 
specie. Thus, partial runs to investigate the contribution to the decrease in specific 
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activity of (i) the synthesis module (including reagents and molecular sieve), (ii) target 
gas and (iii) irradiation process were performed.  
When the contamination due to the synthesis module and reagents was investigated, 
only 15.5 ± 2.7 nmol of non-radioactive CH3I were obtained (Figure 2a, Paper 2). This 
value is lower than the one reported by Iwata et al. (0.2 µmol), which suggested that in 
our configuration the quality of the reagents was appropriate and the evaporation step 
was correctly optimized. In a second step, the contribution of absorbed CO2 in the 
molecular sieve was evaluated. In these experiments, 45.8 ± 11.7 nmol of CH3I were 
obtained (Figure 2a, Paper 2). These experiments were performed after preconditioning 
the molecular sieve column at 250 ºC for one hour to release any absorbed CO2 before 
starting the syntheses. Without preconditioning, values above 300 nmol were found. In 
a third step, the contribution from the nitrogen/oxygen gas mixture, the target chamber 
and the transfer line were investigated. The individual contribution of these factors was 
32.7 ± 24 nmol (Figure 2b, Paper 2). In the last step, the contribution of the irradiation 
process was assessed. In this case, 459.4 ± 209.8, 294.9 ± 253.8, 74.6 ± 84.5 and 159.8 
± 87.5 nmol of CO2 (Figure 2b, Paper 2) were generated during first, second, third and 
fourth-tenth µAh of bombardment, respectively (target current: 24 µA).  
In view of these results and taking into account that non radioactive CO2 was coming, 
mainly, from the target and from the molecular sieve column (when it was not pre-
conditioned) general procedures to be performed routinely before starting a production 
were implemented, including: 
 Loading/unloading the target in order to purge all the CO2 present in the target 
chamber and/or in the transfer line. 
 Loading/bombarding/unloading the target to eliminate, as a result of the 
combustion, all the carrier carbon compounds present in the target chamber. 
 Keeping the target pressurized between productions to prevent the external 
contamination. 
 Preconditioning the molecular sieve for one hour with the aim of desorbing the 
CO2.  




Performing these simple steps before any single production of 11C-labeled compounds 
via the “wet” method allowed us to produce [11C]CH3I with high specific activity 
(above 200 GBq/µmol EOS).  
This substantial improvement in the specific radioactivity was essential to run two 
different projects, one in the clinical and one in the preclinical environment.  
In the first study, [11C]raclopride scans were performed to evaluate antipsychotic-
induced D2 receptor occupancy values in twenty schizophrenic patients and ten healthy 
volunteers. Subjects were also scanned with [123I]IBZM in random order on different 
days within a week to compare the results obtained by PET and by SPECT, 
respectively. To minimize differences among different scans, specific radioactivity of 
both radiotracers had to be maintained constant. [123I]IBZM was purchased from 
Amersham Health, but [11C]raclopride was prepared by [11C]methylation of the 
precursor desmethyl-raclopride with  [11C]CH3I, which was synthesized through the 
“wet” method. By applying the general procedures stated above, not only high but also 
reproducible values of specific radioactivity (23.2 ± 3.2 GBq/µmol, administration time 
>50 min after EOB) were obtained. The results from this study were published in a 
paper entitled “Within-subject comparison of striatal D2 receptor occupancy 
measurements using [
123
I]IBZM SPECT and [
11
C]Raclopride PET” (Annex I).  
In the second study, inflammatory response after transient focal cerebral ischemia was 
determined in rats with PET using the radiotracer [11C]PK11195 (a peripheral 
benzodiazepine receptor ligand), which was also prepared by methylation of the non 
radioactive precursor with  [11C]CH3I, synthesized through the “wet” method. Due to 
the (expected) low PBRs density in the rat brain, specific radioactivity had to be 
maintained as high and constant as possible. Again, specific radioactivity values of 25.0 
± 2.8 GBq/µmol (administration time >50 min after EOB) were obtained. The results 
from this study were published in a paper entitled “Imaging brain inflammation with 
[
11
C]PK11195 by PET and induction of the peripheral-type benzodiazepine receptor 
after transient focal ischemia in rats” (Annex II). 
3.2.3. Conclusions 
The main contribution to non-radioactive CO2 contamination in the final product is 
attributable to the production of this specie during irradiation, probably due to 
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combustion of carbon carriers due to high temperature and pressure. The application of 
some routine protocols before, during and after synthesis processes allows the 
preparation of 11C-labeled radiotracers with high specific activity (~200 GBq/µmol, 
EOB).        
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3.3. PAPERS 3-4: SYNTHESIS OF 13N-LABELED NO DONORS 
3.3.1. Introduction  
Nitric oxide (NO·) is a free radical which easily diffuses across cell membranes. The 
presence of the unpaired electron gives paramagnetic properties to the molecule, 
prevents its dimerization and increases its reactivity with a variety of atoms and free 
radicals.  
NO· is produced in vivo by a group of enzymes called nitric oxide synthases (NOS). 
There are three main isoforms of the NOS enzyme: endothelial NOS (eNOS), neuronal 
NOS (nNOS) and inducible NOS (iNOS). Generation of NO· by eNOS and nNOS 
occurs in short times (seconds) but only relatively small quantities (picomolar range) of 
NO· are produced. In contrast, the activity of iNOS is transcriptionally regulated by 
cytokines and other pro-inflammatory stimuli; maximum induction of iNOS takes 
several hours and much higher (nanomolar) levels of NO· are generated.1,2 The fact that 
NO· can be produced by two kind of enzymes (constitutive and inducible) causes that 
NO· plays different roles (like neurotransmission, immune regulation, vascular smooth 
muscle relaxation and inhibition of platelet aggregation) depending on the origin of its 
formation.  
The importance of NO· has promoted a lot of efforts in the development of new drugs 
able to generate NO· directly or indirectly for therapeutic purposes. These drugs are 
called NO· donors and they may play a role in several physiological and 
pathophysiological processes.  
There is evidence of therapeutic benefit with NO· donor drugs. Thus, organic nitrates, 
which breakdown to form NO· within the coronary and systemic blood vessels, have 
been used as vasodilators for a long time. However, they create tolerance, which limits 
their use. S-nitrosothiols are a promising class of NO· donor drugs which break down to 
form NO· and the corresponding disulphide. The therapeutic benefit of S-nitrosothiols 
has been reported in ischemic heart disease patients, and they are known to act as anti-
platelet agents. Moreover, they do not generate tolerance.  
In spite of the potential applications of S-nitrosothiols as NO· donor drugs, the exact 
mechanisms underlying the role developed by this molecule have not been fully 
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elucidated. Consequently, it would be desirable to have a technique able to detect and 
quantify the presence of S-nitrosothiols and their metabolites in vivo and at trace levels.  
Because of this, and taking into account that GSNO is one of the most stable S-
nitrosothiols and that it can be formed in vivo, a synthesis process for the preparation of 
[13N]GSNO, which might allow an in vivo characterization of the mechanism of action 
of exogenously added S-nitrosothiols was developed.  
With that purpose, the generation of 13N-labeled species in the cyclotron depending on 
the chemical composition of irradiated species was first studied. Once an adequate 
precursor for the synthesis of 13N-labeled nitrosothiols ([13N]NO3
-) was obtained with 
reasonable yields, its reduction (to [13N]NO2
-)  and further reaction with the adequate 
non radioactive precursor (Glutathione, GSH) to yield [13N]GSNO were optimized. 





N-GSNO) as a new potential PET imaging agent”. The 
synthetic route was later applied to the production of other S-[13N]nitrosothiols and an 
automatic remote controlled synthesis box was designed and implemented. The results 
were published in the paper entitled “Fully automated synthesis of 13N-labeled 
nitrosothiols”.         
3.3.2. Results and discussion  
GSNO was first synthesized by the reaction of Glutathione (GSH) with sodium nitrite 
(NaNO2) in acidic media (Scheme 3.2). To reproduce this synthesis in radioactive 
conditions, the production of [13N]GSNO needs to be performed by following four 
steps: (i) generation of nitrogen-13 in the cyclotron as an adequate precursor ([13N]NO3
- 
+ [13N]NO2
-) (ii) chemical reduction of [13N]NO3
- to [13N]NO2
-; (iii) reaction of 
[13N]NO2



























The generation of nitrogen-13 in cyclotrons has been traditionally focused on the 
production of [13N]NH4
+, a radiotracer for myocardial perfusion, through the nuclear 
reaction 16O(p,α)13N by bombarding water with high energy protons. In this case, 
ethanol is used as scavenger to increase the relative amount of [13N]NH4
+ with respect 
to [13N]NO3
- and [13N]NO2
- and the amount of total radioactivity obtained. In the 
current work, efforts were focused towards decreasing the relative amount of 
[13N]NH4
+, and thus some experiments using different quantities of scavenger (0.0, 0.5, 
1.0 and 2.0 mM aqueous ethanol solutions) were performed. In all the cases, the relative 
amount of [13N]NO2
- was less than 5%, but 86.1 ± 1.1% of radioactivity was obtained as 
[13N]NO3
- when purified water was used as irradiated material (see Figure 1A, Paper 3).  
In view of these experimental data, purified water was considered to be optimal for the 
production of [13N]NO3
- + [13N]NO2
-. However, a reduction step was mandatory to 
reduce [13N]NO3
- to [13N]NO2
-. This reduction step was carried out by using a glass 
column filled with cadmium powder. The composition and length of the column were 
also optimized to produce a virtually [13N]NO3
- free solution in the shortest time (see 
Table 2, Paper 3).  
Reaction between GSH and [13N]NO2
- in acidic media to yield [13N]GSNO was also 
optimized in terms of acid concentration and reaction time. Generally, higher 
hydrochloric acid concentrations gave faster reaction rates. Acid concentration of 125 
mM (aqueous solution) gave good radiochemical conversion in 1 minute (88.8 ± 1.1%, 
see Figure 4, Paper 3).  




-)  a purification step was introduced by using solid phase extraction (SPE) 
cartridges. Good radiochemical yields (24.2 ± 2.0%, end of synthesis) and 
radiochemical purities (96.4 ± 0.6%, Table 3, Paper 3) were obtained. No consideration 
was necessary for the non-radioactive precursor in the purification step, because 
reported clinical trials state that 600-1200 mg of GSH injected intravenously in healthy 
volunteers and/or patients produced no toxicological effects.3  
Despite the good radiochemical yields obtained for the preparation of [13N]GSNO in 
this first work, the routine preparation of 13N-labeled nitrosothiols required: (i) the 
development of an easy-to-automate synthesis process, (ii) the design and 
 
implementation of an automatic 
incorporation of a purification process suitable for the elimination of undesired 
byproducts or unreacted precursor
method was developed. The main difference with respect to 
of trapping the [13N]NO2
- solution (after reduction step) in an anion exchange cartridge 
to perform there the nitrosation reaction in a second step. 
reaction mixture could be 
automatic remote controlled box was designed and implemented (Figure 
3.1, the sequence followed for the preparation of the radiotracers is reported.
 
Figure 3.1. Schematic drawing of the automatic remote controlled
the synthesis of S-[13N]nitrosothiols. V1
closed. Normally Open paths in 3
in the SPE cartridge (D1), injection loop (D2) and detection loop (D3).
 
remote controlled synthesis module and (iii) the 
. With this aim, a solid-phase-supported synthesis
the previous work consisted 
By using this approach, t
easily pushed into an HPLC system for purification. An 
 synthesis module implemented for 
-V10 are 2 and 3-way valves. All 2-way valves are normally 
-way valves are shown in black. Radiation detectors were positioned 









The synthesis box showed in Figure 3.1 permitted the manufacture of five S-
[13N]nitrosothiols (S-[13N]nitroso-1-Adamantanethiol, S-[13N]nitroso-cyclohexanethiol, 
S-[13N]nitroso-1-Propanethiol, S-[13N]GSNO and S-[13N]nitroso-2-(N-Acetyl-D-
penicillamido)-2-deoxy-1,3,4,6-tetra-O-acetyl-β-D-glucopyranose or [13N]-RIG-200) 
with high radiochemical yields (from 33.8% to 60.6%, decay corrected, Table 2, Paper 
4) in short times (< 13 min, including purification). The purification step (HPLC) 
ensured chemical and radiochemical purity of the final tracers (Table 2, Paper 4). 
Stability of the radiotracer was checked by HPLC. In all cases, radiochemical purity 
was above 95% at 48 min after EOS (Table 3, Paper 3). 
Table 3.1. Valve opening sequence and explanation of the synthesis process step by step. Coding for 2-
way valves: O, open; C, closed; coding for 3-way valves: L, left; R, right; U, up; D, down.    
STEPa V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 ACTION 
1 C C C C O O L L L U Transfer of 13N solution from cyclotron 
2 O C O O C C R L L U Transfer of 13N solution to cadmium column 
3 O C O O C C L L R U Elution of 13N solution through SPE cartridge 
4 O O C O C C R L R U Fill cadmium column with water 
5 O O C O C C L L R U Elution of rinsing water through SPE cartridge  
6 O C O O C C L L R U Dry SPE with inert gas 
7 C C C C C C R L R U Load precursor in the SPE cartridgeb 
8 C C C C C C R L R U Reaction occursc 
9 C C C C C C L R L U Reaction mixture pushed to loopd 
10 C C C C C C L R L U Start HPLCe 
11 C C C C C C L R L D Collection of desired fractionf  
a The 5 mL collection vial must be loaded with purified water (2 mL) and the syringe driver must be loaded with the precursor 
solution before starting the process.b Syringe driver is started.c Syringe driver is stopped.d Peristaltic pump is started.e Peristaltic 
pump is stopped, Rheodyne valve is switched to inject position, HPLC pump is started.f When signal is detected in radioactive 
detector.  
 
Isolated purified fractions were analyzed by HPLC. Co-elution with reference standard 
compounds confirmed the presence of the desired radiotracers. Although UPLC-MS 
(ESI-TOF) is not appropriate for the identification of nitrosocompounds (due to its 
instability) the presence of some labeled species could be confirmed by this technique. 
GSNO was detected as protonated molecule (m/z = 377.08) and RIG-200 was detected 
as sodium adduct (m/z = 572.15). 
3.3.3. Conclusions  
The in vial reaction of the radioactive precursor [13N]NO2
- with GSH in aqueous acidic 
media leads to the formation of [13N]GSNO with good radiochemical conversion. The 
introduction of a purification step by solid phase extraction cartridges allows obtaining 
radiochemically pure radiotracers (RCP > 95%, EOS). 
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The application of the resin supported method permits the synthesis of 13N-labeled 
nitrosothiols with high radiochemical conversion values (from 60.3 to 74.5%) and high 
radiochemical yields (from 33.8% to 60.6%). Chemically and radiochemically pure 
radiotracers can be obtained by incorporating a purification step by means of 
semipreparative HPLC.  
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3.4. PAPER 5: SYNTHESIS OF 13N-LABELED NITROSAMINES 
3.4.1. Introduction  
In continuation of the work carried out for the synthesis of 13N-labeled nitrosothiols, the 
application of the radioactive precursor [13N]NO2
- to the preparation of other 13N-
labeled compounds was approached. Despite (in theoretical terms) any organic 
molecule can be labeled with carbon-11, and although carbon-11 has some advantages 
with respect to nitrogen-13 as a positron emitter (longer half-life, better known 
chemistry), developing new strategies for 13N-labeling could be very useful especially 
concerning the preparation of radiotracers labeled in different positions, which could 
allow obtaining additional information of specific biological and/or physiological 
processes. 
One clear example of this concept is found in nitrosamines. Nitrosamines are present in 
the human environment, like in cosmetics, tobacco and drugs, and have also been 
detected in food items, such as cured meat, bacon, fish and beer. The carcinogenic 
potential of nitrosamines was first reported by Magee and Barnes1 in 1956. After that, 
many other nitrosamines have been tested in preclinical studies and about 90% of them 
showed potent carcinogenic effects. However, and in spite of the vast literature, the 
exact mechanisms underlying these above mentioned carcinogenic effects are not fully 
elucidated. Although in vitro and ex vivo experiments have been performed to 
understand the carcinogenic mechanism of tobacco-specific nitrosamines, no in vivo 
studies could be done due to the lack of a technique able to detect, in vivo and on real 
time, the biodistribution of nitrosamines and their metabolites.  
Thus, the radioactive precursor [13N]NO2
- was applied to the preparation of 13N-labeled 
nitrosamines via N-[13N]nitrosation of secondary amines. N-nitrosation of amines is a 
well explored reaction in organic synthesis, and different nitrosating agents including 
nitrous acid (HNO2), nitrosyl chloride (NOCl), dinitrogen trioxide (N2O3), dinitrogen 
tetroxide (N2O4), nitrosonium tetrafluoroborate and alkyl nitrites have been applied 
widely for the synthesis of nitrosamines. Another common strategy is the in situ 
generation of the nitrosating agent by treating the amine with nitrite solution in mineral 
acid (Scheme 3.3). However, there are several drawbacks in this synthetic strategy 
under radioactive conditions. Mainly: (i) the low nucleophilicity of secondary amines 
which make the reaction slow in the time scale of nitrogen-13 half-life and (ii) the low 
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amount (sub-micro molar scale) in which the radioactive precursor ([13N]NO2
-) can be 
produced in the cyclotron. Thus, new approaches needed to be developed to 

















Scheme 3.3: Synthesis of nitrosamines by treatment 
of secondary amines with nitrite in acid media. 
3.4.2. Results and discussion  
First attempts to synthesize 13N-labeled nitrosamines were performed following direct 
nitrosation of amines by reaction of [13N]NO2
- with the amine in acidic conditions (like 
shown in Scheme 3.3). Under non-radioactive conditions, and for a wide range of 
temperatures (0 ºC ≤ T ≤ 100 ºC) and acid concentrations (1 ≤ pH ≤ 4.5) very low 
chemical conversions (under 5% in all the cases) were obtained after 10 min of reaction. 
Because of these poor results, the resin-supported methodology (in which trapped 
[13N]NO2
- was reacted with secondary amines dissolved in aqueous acidic media) was 
assayed, with similar results. There was thus the need to develop an alternative strategy 
for the fast, efficient and reproducible preparation of  N-[13N]nitrosamines. 
The method implemented was a combined approach: the first step consisted of trapping 
[13N]NO2
- quantitatively in an anion exchange solid phase extraction cartridge. The 
cartridge was then dried, washed with tetrahydrofuran (THF) and dried again. In a 
second step, a freshly prepared solution containing Ph3P/Br2/secondary amine (1.2: 1.2: 
1 ratio) in dry dichloromethane was passed through the cartridge.  
This method allowed the efficient preparation of N-[13N]nitrosopiperidine, N-
[13N]nitrosomorpholine, N-[13N]nitrosodiisopropylamine and N-[13N]-
nitrosodiethylamine, with radiochemical conversions above 45% in all cases (see Table 
1, Paper 5).  
The purification was carried out by elution of the reaction mixture through a C-18 SPE 
cartridge to selectively retain the desired radiotracer. After rinsing with purified water, 




(major radiochemical impurity) and bromotriphenylphosphonium bromide (major 
chemical impurity) were removed. Radiochemical yields were between 34.0 and 40.7% 
(decay corrected), in a synthesis time < 10 min (Table 1, Paper 5). Radiochemical purity 
was above 99% in all cases. 
3.4.3. Conclusions  
The reaction of resin trapped [13N]NO2
- with secondary amines in the presence of Ph3P 
and Br2 allows the synthesis of the corresponding N-[
13N]nitrosamines with excellent 
radiochemical conversion and good radiochemical yields. 
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3.5. PAPER 6: SYNTHESIS OF 13N-LABELED AZO COMPOUNDS 
3.5.1. Introduction  
Some neurodegenerative disorders, like Alzheimer’s disease (AD), are associated to the 
depositions of senile plaques (SPs) and neurofibrillary tangles (NFTs), which contain β-
amyloid (Aβ) peptides and highly phosphorylated tau proteins in specific regions of the 
brain.1 Especially in AD, the Aβ far overweighs the other amyloid related protein 
components in a total mass basis in most brain regions,2 and its neurotoxicity is 
dependent on aggregation of Aβ into β-sheet fibrils.3  
The above mentioned β-sheet structure of Aβ deposits has historically facilitated the 
detection of such deposits. Thus, Congo Red (Figure 3.2) has been used for decades to 
identify amyloid deposits in post-mortem tissue, due to its intense color and selective 
affinity for β-sheet structures.4 However, the detection of β-amyloid plaques in the brain 
by using Congo Red can be only performed in postmortem studies.  
Currently, there are a lot of efforts dedicated to the development of PET and SPECT 
imaging probes able to cross the Blood Brain Barrier (BBB) and bind to β-Amyloid 
deposits in vivo. The possibility to perform in vivo studies to visualize on real time the 
deposition of β-Amyloid plaques would give further understanding about the evolution 
of the pathology. Moreover, these tracers could be used as probes for the early diagnose 
of the pathology and would accelerate the discovery of potential effective therapeutic 
agents. Thus, in the recent years, a number of groups have developed promising PET 
probes (Figure 3.3) including [11C]-2-4’(methylaminophenyl)-6-hydroxybenzothiazole 




















Figure 3.2. Chemical structure of Congo Red, used for the identification 













































Figure 3.3. Chemical structure of some PET tracers developed for the in vivo detection of Aβ plaques: 
[11C]PIB, [11C]SB-13, [18F]BAY94-9172, [11C]BF-227, and [18F]-FDDNP. 
Following the previous work concerning the potential applications of the radioactive 
precursor [13N]NO2
- for the preparation of 13N-labeled compounds, and taking 
advantage of the well-known chemical reaction for the synthesis of azo compounds via 
diazonium salt formation (Figure 3.4), the synthesis of 13N-labeled azo compounds 
(which could be potentially used for the in vivo  detection of Aβ plaques in 
neurodegenerative disorders) was approached. In non radioactive conditions, the 
synthetic procedure includes two steps. In a first step, the diazonium salt is formed by 
the reaction of an aromatic primary amine with NO2
- in acidic conditions. The second 
step involves the reaction of the diazonium salt with the adequate aromatic moiety to 
yield the final compound, which is usually isolated by precipitation. 
When applying the synthesis route in radioactive conditions (this is, using [13N]NO2
- as 
radioactive precursor) modifications have to be introduced because precipitation is not 
possible. Thus, a labeling strategy was developed and applied to the preparation of five 
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different azo compounds. Some modifications to the synthesis box presented in section 
3.3.2 were implemented to automatically perform the above mentioned synthesis 
procedure (see Figure 3 and Table 3, Paper 6). 
3.5.2. Results and discussion  
The synthesis of 13N-labeled azo compounds was approached by a three steps 
methodology (see Figure 3.5). In the first step, [13N]NO3
- was reduced to [13N]NO2
-, 
which was trapped in an anion exchange resin cartridge (SPE). In a second step, 
[13N]NO2
- was reacted in situ  (into the SPE) with the aromatic primary amine 
(dissolved in acidic media) to yield the corresponding 13N-labeled diazonium salt. The 
labeled compound was then pushed into a vial containing the aromatic non radioactive 
precursor B. The reaction between the labeled and the unlabeled specie (see reaction 
times and temperatures, Table 1, Paper 6) led to the formation of the desired azo 
compound, which was purified by semipreparative HPLC. 
Isolated purified fractions were analyzed by HPLC. Co-elution with reference standard 
compounds confirmed the presence of the desired radiotracers. The presence of labeled 
species could be confirmed by UPLC-MS (ESI-TOF).  
This method allowed the efficient preparation of 4-phenyl-[13N]-azophenol, p-phenyl-
[13N]-azoaniline, 4-(Dimethylamino)-[13N]-azobenzene, 4-[4-(Dimethylamino)phenyl-
[13N]-azo]benzenesulfonic acid and 4-(4-hydroxy-phenyl-[13N]-azo)-benzenesulfonic 

















































Figure 3.5. Synthesis of 13N-labeled azo compounds through a three steps procedure. 
 
Radiochemical yields were between 20.44  and 47.21% (decay corrected, Table 2, Paper 
6). The stability of the resulting radiotracers was checked at 25ºC. Radiochemical purity 
values >99.9% were obtained 60 minutes after the end of the synthesis in all cases. 
Specific radioactivity values were checked by HPLC. Values between 4.6 and 8.8 
(corrected to the end of the synthesis, Table 2, Paper 6) were obtained.  
3.5.3. Conclusions 
The reaction of resin trapped [13N]NO2
- with primary aromatic amines allows the 
synthesis of the corresponding 13N-labeled diazonium salts. Further reaction with 
aromatic non radioactive precursors (amines or alcohols) leads to the formation of azo 
compounds with good radiochemical conversions, acceptable radiochemical yields (20.4 
– 47.2%, decay corrected) and excellent radiochemical purity values (> 99.9%).  
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PAPER 6:    Convenient synthesis of 
13
N-labeled azo compounds: a new 
route for the preparation of amyloid imaging PET probes 
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1- The reaction of [11C]CH3I (produced via the “wet” method) with a solution of the 
non radioactive precursor (L-homocysteine) in water/ethanol under basic conditions 
permits the synthesis of L-[methyl-11C]methionine in good radiochemical yields 
(38.4 ± 4.1%, EOS) in a fully automated process by using the captive solvent 
method. The simplicity of the process and the implementation of an adequate 
cleaning sequence between consecutive runs permits multiple productions within 
one day with minimal radiological exposure. 
2- The main contribution to non-radioactive CO2 contamination in the final product is 
attributable to the production of this specie during irradiation, probably due to 
combustion of carbon carriers due to high temperature and pressure. The application 
of some routine protocols before, during and after synthesis processes allows the 
preparation of 11C-labeled radiotracers with high specific activity (~200 GBq/µmol, 
EOB).         
3- The in vial reaction of the radioactive precursor [13N]NO2
- with GSH in aqueous 
acidic media leads to the formation of [13N]GSNO with good radiochemical 
conversion. The introduction of a purification step by solid phase extraction 
cartridges allows obtaining radiochemically pure radiotracers (RCP > 95%, EOS). 
4- The application of the resin supported method permits the synthesis of 13N-labeled 
nitrosothiols with high radiochemical conversion values (from 60.3 to 74.5%) and 
high radiochemical yields (from 33.8% to 60.6%). Chemically and radiochemically 
pure radiotracers can be obtained by incorporating a purification step by means of 
semipreparative HPLC.  
5- The reaction of resin trapped [13N]NO2
- with secondary amines in the presence of 
Ph3P and Br2 allows the synthesis of the corresponding N-[
13N]nitrosamines with 
excellent radiochemical conversion and good radiochemical yields. 
6- The reaction of resin trapped [13N]NO2
- with primary aromatic amines allowed the 
synthesis of the corresponding 13N-labeled diazonium salts. Further reaction with 
aromatic non radioactive precursors (amines or alcohols) lead to the formation of 
azo compounds with good radiochemical conversions, acceptable radiochemical 













ANNEX I:  
Within-subject comparison of striatal D2 receptor occupancy measurements using 
[
123
I]IBZM SPECT and [
11
C]Raclopride PET  
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ANNEX II:  
Imaging brain inflammation with [
11
C]PK11195 by PET and induction of the peripheral-type 
benzodiazepine receptor after focal ischemia in rats  
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